MedTrace Logo

Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223

NCT03223727 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-04-18

No results posted yet for this study

Summary

This registry aims to evaluate the efficacy of Rad-223 treatment in a non-study population of CRPC patients treated earlier with Docetaxel and patients not treated earlier with Docetaxel and efficacy of the first subsequent therapy. The indication for treatment with Radium-223 will be at the physician's decision. All patients treated with Radium-223 can be included in this registry. The registry only dictates the collection of base line characteristics, expansion of regular blood tests and patient reported pain scores.

Conditions

Interventions

DIAGNOSTIC_TEST

Blood tests

Blood tests for several bone markers (see summary)

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Andre Bergman, MD, PhD · The Netherlands Cancer Institute

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-30
Primary Completion
2022-02-03
Completion
2023-02-03

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03223727 on ClinicalTrials.gov